Purpose

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Subject must have at least one of the clinical indications before device implant in adherence with ACC/AHA/HRS/ESC dual chamber pacing guidelines 2. Subject is ≥ 18 years of age or age of legal consent, whichever age is greater 3. Subject has a life expectancy of at least one year 4. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams 5. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC

Exclusion Criteria

  1. Subject is currently participating in another clinical investigation that may confound the results of this study as determined by the Sponsor 2. Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period 3. Subject has presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could confound the assessment of the investigational device and/or implant procedure, limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results 4. Subject has a known allergy or hypersensitivity to < 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material listed in the IFU 5. Subject has an implanted vena cava filter or mechanical tricuspid valve prosthesis 6. Subject has pre-existing, permanent endocardial pacing or defibrillation leads (does not include lead fragments) 7. Subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device 8. Subject has an implanted leadless cardiac pacemaker (except for an Aveir ventricular leadless pacemaker) 9. Subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators) 10. Subject is unable to read or write

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
Prospective, multi-center, international, single-arm, pivotal investigational study
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Single Arm
Non randomized arm
  • Device: Aveir DR Leadless Pacemaker System
    Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium

Recruiting Locations

Washington Hospital Center
Washington, District of Columbia 20010
Contact:
Nebu Alexander
Nebu.Alexander@medstar.net

More Details

Status
Recruiting
Sponsor
Abbott Medical Devices

Study Contact

Binh Ngo
8184932060
binh.ngo1@abbott.com

Detailed Description

The purpose of this clinical investigation is to evaluate the clinical safety and effectiveness of the Aveir DR Leadless Pacemaker system in a patient population indicated for a DDD(R) pacemaker. Subjects participating in the study are followed through at least 12 months with data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.